| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Neurology, Vol 50, Issue 6 1778-1783, Copyright © 1998 by American Academy of Neurology
ARTICLES |
J Palace, J Newsom-Davis and B Lecky
Department of Clinical Neurology, University of Oxford, UK.
We compared prednisolone (PRED) and azathioprine (AZA) versus prednisolone alone in the treatment of MG. Prednisolone alone or combined with azathioprine is widely used in the treatment of MG, but no randomized placebo-controlled comparative trial data are available. The prednisolone dose and clinical outcome were compared in a multicenter randomized double-blind study of 34 MG patients who were followed up for 3 years. One group (PRED + AZA) received prednisolone (on alternate days) plus azathioprine (2.5 mg/kg); the other group received prednisolone on alternate days plus placebo (PRED + PLAC). Initial high-dose prednisolone (1.5 mg/kg on alternate days) was tapered at remission to the minimal dose required to maintain remission. The prednisolone dose did not differ significantly between the two groups at 1 year (median values: PRED + AZA, 37.5 mg on alternate days; PRED + PLAC, 45 mg on alternate days) but was reduced at 2 and 3 years in the PRED + AZA group (median value at 3 years: PRED + AZA, 0 mg on alternate days; PRED + PLAC, 40 mg on alternate days; p=0.02). Relapses and failures to remit over the 3 years were more frequent in the PRED + PLAC group. There was a sharp rise in the anti- acetylcholine receptor (AChR) titers in the PRED + PLAC group at 2 years. Incidence of side effects was slightly less in the PRED + AZA group. Azathioprine as an adjunct to alternate day prednisolone in the treatment of antibody-positive generalized MG reduces the maintenance dose of prednisolone and is associated with fewer treatment failures, longer remissions, and fewer side effects.
This article has been cited by other articles:
|
|
 |
|
  R. Gold, R. Hohlfeld, and K. V. Toyka Review: Progress in the treatment of myasthenia gravis Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 99 - 114. [Abstract] [PDF]
|
|
|
|
 |
|
 D. B. Sanders, I. K. Hart, R. Mantegazza, S. S. Shukla, Z. A. Siddiqi, M.H.V. De Baets, A. Melms, M. W. Nicolle, N. Solomons, and D. P. Richman An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis Neurology, August 5, 2008; 71(6): 400 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Massacesi, A. Parigi, A. Barilaro, A. M. Repice, G. Pellicano, A. Konze, G. Siracusa, R. Taiuti, and L. Amaducci Efficacy of Azathioprine on Multiple Sclerosis New Brain Lesions Evaluated Using Magnetic Resonance Imaging Arch Neurol, December 1, 2005; 62(12): 1843 - 1847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Konishi, Y Yoshiyama, M Takamori, T Saida, and the Japanese FK506 MG Study Group Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus) J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 448 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Ciafaloni Mycophenolate mofetil and myasthenia gravis Lupus, March 1, 2005; 14(3_suppl): s46 - s49. [Abstract] [PDF]
|
|
|
|
|
|
E. Ciafaloni Mycophenolate mofetil and myasthenia gravis Lupus, January 1, 2005; 14(1_suppl): s46 - s49. [Abstract] [PDF]
|
|
|
|
 |
|
 B R Thanvi and T C N Lo Update on myasthenia gravis Postgrad. Med. J., December 1, 2004; 80(950): 690 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vincent, C. Buckley, J. M. Schott, I. Baker, B.-K. Dewar, N. Detert, L. Clover, A. Parkinson, C. G. Bien, S. Omer, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis Brain, March 1, 2004; 127(3): 701 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Richman and M. A. Agius Treatment of autoimmune myasthenia gravis Neurology, December 23, 2003; 61(12): 1652 - 1661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hill THE NEUROMUSCULAR JUNCTION DISORDERS J. Neurol. Neurosurg. Psychiatry, June 1, 2003; 74(90002): ii32 - 37. [Full Text] [PDF]
|
|
|
|
|
|
P Maddison, B Lang, K Mills, and J Newsom-Davis Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer J. Neurol. Neurosurg. Psychiatry, February 1, 2001; 70(2): 212 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jaretzki III, R. J. Barohn, R. M. Ernstoff, H. J. Kaminski, J. C. Keesey, A. S. Penn, and D. B. Sanders Myasthenia gravis: Recommendations for clinical research standards Neurology, July 12, 2000; 55(1): 16 - 23. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jaretzki III, R. J. Barohn, R. M. Ernstoff, H. J. Kaminski, J. C. Keesey, A. S. Penn, and D. B. Sanders Myasthenia gravis: recommendations for clinical research standards Ann. Thorac. Surg., July 1, 2000; 70(1): 327 - 334. [Full Text] [PDF]
|
|
|
|
 |
|
 E M. Shanahan, M. D Smith, and M. J Ahern Pulse methylprednisolone therapy for arthritis causing muscle weakness Ann Rheum Dis, September 1, 1999; 58(9): 521 - 522. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
